Clinical Trial Update: CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CASCARA combining castration sensitivity strategies with carboplatin, cabazitaxel, and abiraterone in prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• CARBOPLATIN (Carboplatin)
• CASCARA
• Cabazitaxel (cabazitaxel)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING